Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
3.480
-0.370 (-9.61%)
At close: May 9, 2025, 4:00 PM
3.480
0.00 (0.00%)
After-hours: May 9, 2025, 4:05 PM EDT

Company Description

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases.

Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024.

The company was incorporated in 2019 and is based in Palo Alto, California.

Kalaris Therapeutics, Inc.
Kalaris Therapeutics logo
Country United States
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 14
CEO Andrew Oxtoby

Contact Details

Address:
628 Middlefield Road
Palo Alto, California 94301
United States
Website kalaristx.com

Stock Details

Ticker Symbol KLRS
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001754068
CUSIP Number 482929106
ISIN Number US4829291065

Key Executives

Name Position
Andrew Oxtoby President, Chief Executive Officer and Director
Dr. Srinivas Akkaraju M.D., Ph.D. Director and Co-Founder
Dr. Michael Philip Dybbs Ph.D. Director and Co-Founder
Dr. Napoleone Ferrara M.D. Director and Co-Founder
Dr. Samir C. Patel M.D. Director and Co-Founder
Brett R. Hagen Principal Financial Officer and Principal Accounting Officer
Dr. Jeffrey Nau MMS, Ph.D. Chief Operating Officer
Dr. Matthew Feinsod M.D. Chief Medical Officer